Evidence map›Paper›PMID 40459529›Full record

ArticleCancer immunology research2025

CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice.

Ziye Song, Youkyung Lim, Anneloes van Krimpen, Mitchell A A Geleijnse, Manon Messchendorp, Jane S A Voerman, Ling Li, Emma G M Tondeur, Gunja Mishra, Brett J Hos and 5 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ziye SongDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-2274-6028
Youkyung Lim *Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0009-0008-5119-9810
Anneloes van Krimpen *Department of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-3226-0961
Mitchell A A GeleijnseDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0009-0003-9865-5485
Manon MesschendorpDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0009-0004-1241-4996
Jane S A VoermanDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0009-0000-6516-4098
Ling LiDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0009-0003-5124-9228
Emma G M TondeurDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-5253-8847
Gunja MishraDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-5869-2765
Brett J HosDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-1158-5142
Dwin G B GrashofDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-4169-9888
Ralph StadhoudersDepartment of Pulmonary Medicine, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-1060-5607
Harmen J G van de WerkenDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-9794-1477
Peter D KatsikisDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0001-7690-5218
Christopher SchlieheDepartment of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0002-1923-8620

Funding

Investigating PROTAC-mediated antigen degradation as a novel strategy to enhance cytotoxic T-cell responses against cancer in vivo.R21CA274064 · NCI · ERASMUS MEDICAL CENTER · PI SCHLIEHE, CHRISTOPHER · 2022 to 2022
$278k
Chinese Scholarship Council 201906210055Chinese Scholarship Council 201906270271Daniel den Hoed FoundationDutch Research Council 09150172010068LEaDing Postdoc fellowship 707404National Institutes of Health (NIH) CA274064NCI NIH HHS R21 CA274064
6 · The paper itself

Abstract

Cytotoxic T lymphocytes screen cells for signs of infection and transformation by recognizing peptides displayed on MHC class I molecules. Next to canonical ATG-initiated open reading frames (ORF), noncanonical translation can result in synthesis of nonconventional or "cryptic" polypeptides. These can originate from translation initiation at noncanonical start codons, a process previously associated with inflammation and oncogenic transformation. Cryptic translation products are efficiently presented on MHC class I molecules and therefore increasingly recognized as potential targets for cancer immunotherapy. In this study, we studied the impact of localization of a CTG-initiated ORF relative to a canonical ATG start codon on cryptic expression after innate immune stimulation. We generated immortalized C57BL/6J mouse-derived bone marrow progenitor cells (HoxB8) expressing tandem minigene constructs, which encoded a CTG-driven chicken ovalbumin-derived SIINFEKL (S8L) epitope (CTG-S8L; H-2Kb restriced) either up- or downstream of a canonical ATG-initiated UTY-derived peptide WI9. The treatment of HoxB8-derived macrophages with Toll-like receptor agonists enhanced position-independent CTG-S8L translation, without affecting ATG-driven expression. Downstream CTG-S8L translation was driven by leaky scanning or ribosome re-initiation rather than read-through translation. Mouse AE17 mesothelioma and B16F10 melanoma cells expressing cryptic S8L either up- or downstream of a canonical ORF were efficiently killed by H-2Kb/S8L-restriced OT-I T cells in vitro, even though their antigen expression levels were extremely low. Mice implanted with tumors expressing cryptic S8L showed delayed tumor progression in vivo. In summary, our study contributes to the characterization of noncanonical start codon-driven cryptic antigen translation and highlights its potential for cancer immunotherapy.

Indexed as

Codon, InitiatorPeptidesProtein BiosynthesisToll-Like ReceptorsAnimalsCell Line, TumorHumansMacrophagesMelanoma, ExperimentalMiceMice, Inbred C57BLOpen Reading FramesT-Lymphocytes, CytotoxicCodon, InitiatorPeptidesToll-Like Receptors

Identifiers

PMID40459529
PMCPMC12314520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.